Autopsy report · NCT00486759

A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

“Due to an unfavorable benefit/risk ratio.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 4 years 4 months before it stopped.
• 787 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Hoffmann-La Roche

Sponsor type

Industry

Conditions

B-cell Lymphoma

Interventions

Bevacizumab; Rituximab; CHOP; Placebo

Participants

787

Sites

266

Countries

Argentina, Australia, Austria, Brazil, Canada, China, Colombia, Czechia, Ecuador, France, Germany, Greece and more

Trials that died the same way

• Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML
  “Due to financial reasons.” (62% match in meaning)
• Mesenchymal Stem Cells in the Treatment of Refractory Primary Immune Thrombocytopenia
  “Due to corporate strategic adjustment.” (61% match in meaning)
• A Pharmacokinetic Analysis of Posaconazole in Lung Transplant Recipients (MK-5592-105)
  “Study terminated due to an unfavorable risk-benefit analysis” (60% match in meaning)
• To Study and Compare the Clinical Course and Development of Organ Failure in Severe Acute Hepatitis Without Ascites, Non-cirrhotic and Cirrhotic Patients With Ascites [Acute on Chronic Liver Failure] and Acute Deterioration of Previously Decompensated Cirrhosis.
  “Due to lack of funds” (59% match in meaning)
• Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
  “Due to strategic reasons” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.